Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $18.33

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $18.33.

Several analysts have weighed in on the stock. HC Wainwright dropped their target price on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating on the stock in a research report on Thursday, April 3rd. Morgan Stanley dropped their price objective on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of large investors have recently added to or reduced their stakes in KYTX. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Kyverna Therapeutics during the fourth quarter worth approximately $34,000. Squarepoint Ops LLC purchased a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $43,000. Corton Capital Inc. purchased a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $45,000. Corebridge Financial Inc. raised its holdings in Kyverna Therapeutics by 42.3% in the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company's stock valued at $48,000 after acquiring an additional 3,810 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kyverna Therapeutics by 53.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company's stock valued at $53,000 after purchasing an additional 4,990 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Price Performance

Shares of KYTX stock traded up $0.02 during mid-day trading on Friday, hitting $2.33. 71,872 shares of the stock traded hands, compared to its average volume of 418,339. Kyverna Therapeutics has a 52-week low of $1.78 and a 52-week high of $17.55. The stock has a market cap of $100.74 million, a P/E ratio of -0.67 and a beta of 2.57. The stock's fifty day moving average is $2.27 and its two-hundred day moving average is $3.54.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.01). As a group, equities analysts forecast that Kyverna Therapeutics will post -3.29 EPS for the current fiscal year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.